Healthcare Industry News: perfluorocarbon
News Release - July 1, 2008
Synthetic Blood International Changes Name to Oxygen Biotherapeutics, Inc.Stock Trading Symbol Changes to OXBO
COSTA MESA, Calif.--(HSMN NewsFeed)--Effective today, Oxygen Biotherapeutics, Inc. is the new name for the company previously known as Synthetic Blood International, Inc. (OTCBB:SYBD ). Effective with the opening of trading today, the company’s new trading symbol will be OXBO. It will continue to trade on the Over-the-Counter Bulletin Board.
“Our new name better reflects the broader scope of our development activities,” said company chairman and CEO Chris J. Stern, DBA. “We have several exciting bio-therapeutic applications for Oxycyte®, yet none of them is synthetic blood. What we’re doing is developing advanced oxygen-based therapies using Oxycyte including traumatic brain injury, sickle cell pain crisis, wound treatment, organ transport, heart attack, stroke, and, as a long shot, spinal cord injury.” Oxycyte is the company's perfluorocarbon (PFC) therapeutic oxygen carrier.
The company’s website will be www.oxybiomed.com. Company email addresses will also change to end in @oxybiomed.com.
About Oxygen Biotherapeutics, Inc.
Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and continuous substrate monitoring. The Company has under development a perfluorocarbon therapeutic oxygen carrier and liquid ventilation product and an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs and medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including acute respiratory distress syndrome, stroke, myocardial infarction, surgery, trauma, malignant tumors and diabetes. For further information, visit www.oxybiomed.com.
Caution Regarding Forward-Looking Statements
This news release contains certain forward-looking statements by Oxygen Biotherapeutics, Inc. that involve risks and uncertainties and reflect the company's judgment as of the date of this release. These statements include descriptions of and references to potential development and applications of Oxycyte. Actual events or results may differ from Oxygen Biotherapeutics, Inc.'s expectations. There can be no assurance that any such research will be successful, that Oxycyte will be approved for market by the FDA, or that if approved will gain market acceptance. Additional information concerning these and other risk factors affecting Oxygen Biotherapeutics, Inc.'s business can be found in the company's public periodic filings with the Securities and Exchange Commission, which are available via www.oxybiomed.com. Oxygen Biotherapeutics, Inc. disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Source: Oxygen Biotherapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.